EU secures 225M doses of CureVac COVID-19 vaccine

By The Science Advisory Board staff writers

November 17, 2020 -- The European Commission approved a fifth contract with CureVac for the initial purchase of 225 million doses on behalf of all European Union (EU) member states, plus an option to request up to an additional 180 million doses.

The commission has already signed contracts with AstraZeneca, Sanofi- GlaxoSmithKline, Janssen, and BioNTech/Pfizer, and is in exploratory talks with Moderna. This portfolio will ensure Europe is well-prepared for vaccination once the vaccines have been proven safe and effective. Member states can also decide to donate the vaccine to lower or middle-income countries or to redirect it to other European countries. To date, the commission has secured at least 1.2 billion doses.

Germany-based CureVac signed an $89 million loan agreement with the European Investment Bank on July 6 for the development and large-scale production of vaccines, including its COVID-19 vaccine candidate. The company is developing a new class of vaccines based on messenger RNA delivered by lipid nanoparticles.

CureVac released positive interim phase I data for its CVnCoV vaccine candidate on November 10 and is planning to initiate a phase IIb/III clinical trial by the end of 2020.

Pfizer, BioNTech finalize supply deal with EU for COVID-19 vaccine
Pfizer and BioNTech, developers of BNT162b2, a messenger RNA-based SARS-CoV-2 vaccine candidate, have reached an agreement with the European Commission...
J&J to supply EU with 200M COVID-19 vaccine doses
Johnson & Johnson has received approval from the European Commission to supply 200 million doses of Janssen Pharmaceutical's COVID-19 vaccine...
Moderna discusses supplying 80M doses of mRNA-1273 to EU
Moderna is in discussions with the European Commission to supply 80 million doses of messenger RNA (mRNA)-1273, Moderna's COVID-19 vaccine candidate,...
Sanofi, GSK get $2.1B for COVID-19 vaccine
The U.S. government will provide up to $2.1 billion to Sanofi and GlaxoSmithKline (GSK) for the development and manufacturing of a recombinant protein-based...
Europe raises 7.4B euros for coronavirus response
On May 4, a group of nations and the European Commission raised 7.4 billion euros ($8 billion U.S.) to help make up for funding shortfalls in...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter